Contributing factors to heparin resistance during cardiopulmonary bypass

被引:1
|
作者
Yamashiro, Tomoaki [1 ]
Takami, Yoshiyuki [2 ]
Takagi, Yasushi [2 ]
机构
[1] Fujita Hlth Univ Hosp, Dept Clin Engn, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan
[2] Fujita Hlth Univ, Dept Cardiovasc Surg, Sch Med, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan
关键词
Heparin resistance; Cardiopulmonary bypass; Activated clotting time; Unfractionated heparin; DOSE-RESPONSE; INHIBITION; ANTITHROMBIN; EFFICACY; THROMBIN; AFFINITY; ALBUMIN; THERAPY; BINDING; FIBRIN;
D O I
10.1007/s10047-024-01435-1
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Since the risk factors for heparin resistance (HR) before cardiopulmonary bypass (CPB) have not been fully clarified, this study investigated the contributing factors for HR after the initial unfractionated heparin (UFH) dose of 500 IU/kg. We retrospectively analyzed the data of 371 patients who underwent CPB surgery, with the initial UFH dose of 500 IU/kg, between May 2017 and December 2021. We defined HR as the failure to achieve activated clotting time (ACT) of > 480 s after the initial UFH dose of 500 IU/kg. HR was observed in 36 patients (9.7%) (HR group), while HR was not observed in 335 patients (control group). The HR group included significantly more patients with preoperative use of UFH, with significantly higher white blood cell counts, fibrinogen, fibrinogen degradation products, d-dimer, and C-reactive protein, and lower hemoglobin and albumin. The multivariable logistic regression analysis identified albumin (OR: 3.09, 95% CI 1.3504-7.0845, p = 0.0075) and fibrinogen (OR: 0.99, 95% CI 0.9869-0.9963, p = 0.0003) as independent predictors for HR. Using the Youden index, the cutoffs of albumin and fibrinogen were calculated as 3.8 g/dL and 303 mg/dL, respectively. The receiver operating characteristic curves showed the predictive performance of albumin (area under the curve (AUC): 0.78, sensitivity: 65%, specificity: 81%) and fibrinogen (AUC: 0.77, sensitivity: 56%, specificity: 88%). The incidence of HR after the initial UFH dose of 500 IU/kg was 9.7%. The preoperative albumin < 3.8 g/dL and fibrinogen > 303 mg/dL were independent predictors for HR.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 50 条
  • [1] HEPARIN RESISTANCE DURING CARDIOPULMONARY BYPASS
    HICKS, GL
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1983, 86 (04): : 633 - 633
  • [2] Heparin resistance during cardiopulmonary bypass
    Jung, Hyun Ju
    Kim, Jong Bun
    Im, Kyong Shil
    Oh, Seung Hwa
    Lee, Jae Myeong
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2009, 10 (12) : 940 - 941
  • [3] HEPARIN RESISTANCE DURING CARDIOPULMONARY BYPASS - THE ROLE OF HEPARIN PRETREATMENT
    ESPOSITO, RA
    CULLIFORD, AT
    COLVIN, SB
    THOMAS, SJ
    LACKNER, H
    SPENCER, FC
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1983, 85 (03): : 346 - 353
  • [4] Paraprotein associated heparin resistance during cardiopulmonary bypass
    Khuong, Jacqueline N.
    Forsyth, Cecily J.
    Manuel, Lucy
    Kingsford-Smith, Kate
    Srivastava, Arpit
    Bassin, Levi
    PERFUSION-UK, 2023, 38 (06): : 1319 - 1321
  • [5] Heparin Sensitivity and Resistance: Management During Cardiopulmonary Bypass
    Finley, Alan
    Greenberg, Charles
    ANESTHESIA AND ANALGESIA, 2013, 116 (06): : 1210 - 1222
  • [6] Heparin Resistance During Cardiopulmonary Bypass in Adult Cardiac Surgery
    Chen, Yufan
    Phoon, Priscilla Hui Yi
    Hwang, Nian Chih
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2022, 36 (11) : 4150 - 4160
  • [7] HEPARIN RESISTANCE PRIOR TO CARDIOPULMONARY BYPASS
    ANDERSON, EF
    ANESTHESIOLOGY, 1986, 64 (04) : 504 - 507
  • [8] Heparin management during cardiopulmonary bypass
    Linden, MD
    Erber, WN
    Schneider, M
    JOURNAL OF CARDIOVASCULAR SURGERY, 2001, 42 (03): : 431 - 433
  • [9] HEPARIN MONITORING DURING CARDIOPULMONARY BYPASS
    SALEEM, A
    SHENAQ, SS
    YAWN, DH
    HARSHBERGER, K
    DIEMUNSCH, P
    MOHINDRA, P
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 1984, 14 (06): : 474 - 479
  • [10] Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass
    Audrick Gibert
    Julien Lanoiselée
    Isabelle Gouin-Thibault
    Adeline Pontis
    Kasra Azarnoush
    Andranik Petrosyan
    Nathalie Grand
    Serge Molliex
    Jérome Morel
    Laurent Gergelé
    Sophie Hodin
    Valérie Bin
    Robin Chaux
    Xavier Delavenne
    Edouard Ollier
    Clinical Pharmacokinetics, 2024, 63 : 211 - 225